Rajan Saggar, MD
Pulmonary Disease · Los Angeles, CANPI 1255351854
Payments from drug & device makers
Across 936 payments — averaging $3523.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2.1M
- United Therapeutics Corporation$689K
- Actelion Pharmaceuticals, Ltd$303K
- Actelion Pharmaceuticals US, Inc.$71K
- Enzyvant Therapeutics, Inc.$30K
- Insmed, Inc.$24K
- plus $48K from 15 others
Across 4 payments — averaging $657.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 125 | $2,133,289 |
| United Therapeutics Corporation | 446 | $688,935 |
| Actelion Pharmaceuticals, Ltd | 10 | $302,875 |
| Actelion Pharmaceuticals US, Inc. | 201 | $70,824 |
| Enzyvant Therapeutics, Inc. | 1 | $30,220 |
| Insmed, Inc. | 19 | $23,992 |
| Bayer | 63 | $12,553 |
| Sumitomo Pharma America, Inc. | 1 | $9,686 |
| GSK | 14 | $8,202 |
| Liquidia Technologies, Inc. | 14 | $7,743 |
| Genentech, Inc. | 2 | $4,256 |
| Janssen Research & Development, LLC | 1 | $3,650 |
| Boehringer Ingelheim | 3 | $616 |
| Inari Medical, Inc. | 3 | $495 |
| Sandoz | 23 | $246 |
| Johnson & Johnson(2 entities) | 5 | $191 |
| Genentech USA, Inc. | 1 | $147 |
| Grifols USA, LLC | 1 | $125 |
| AstraZeneca | 1 | $122 |
| La Jolla Pharmaceutical Company | 1 | $27 |
| Abbott | 1 | $20 |
How this compares
$3,298,215 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Los Angeles
- Toby MaherLos Angeles$27.6M
- Andrew WachtelLos Angeles$5.9M
- Michael RothLos Angeles$4.5M
- Stephen Samuel WeigtLos Angeles$2.1M
- Robert WolfeLos Angeles$1.9M
- Igor BarjaktarevicLos Angeles$1.9M
- Shelley ShapiroLos Angeles$1M
- Victor TapsonLos Angeles$931K
- John BelperioLos Angeles$905K
- Sivagini GaneshLos Angeles$816K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.